OLYMPUS CORP/S (OTCMKTS:OCPNY) – Equities researchers at Jefferies Financial Group issued their FY2022 earnings estimates for shares of OLYMPUS CORP/S in a research report issued on Thursday, June 13th. Jefferies Financial Group analyst M. Nakanomyo expects that the company will post earnings per share of $0.60 for the year.
Several other equities analysts also recently commented on OCPNY. ValuEngine raised OLYMPUS CORP/S from a “hold” rating to a “buy” rating in a research report on Tuesday, March 5th. Zacks Investment Research raised shares of OLYMPUS CORP/S from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Wednesday, April 17th.
OCPNY opened at $11.42 on Friday. OLYMPUS CORP/S has a 52-week low of $6.26 and a 52-week high of $12.30. The stock has a market cap of $15.82 billion, a P/E ratio of 228.45, a P/E/G ratio of 2.46 and a beta of 0.70. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.05 and a current ratio of 1.59.
OLYMPUS CORP/S Company Profile
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through four segments: Medical Business, Scientific Solutions Business, Imaging Business, and Others. It offers endoscopic video endoscopy systems, endoscopic ultrasound systems, ultrasound endoscopes and probes, endoscopic ultrasound observation devices, capsule endoscopy systems, integrated documentation systems, therapeutic equipment, and ancillary products; cleaning, disinfecting, and sterilization systems; gastrointestinal, colono, duodeno, and broncho endoscopes; endoscopy products for gastroenterological surgery, bronchial surgery, urology, gynecology, orthopedic surgery, neurosurgery, and anesthesiology, as well as ear, nose, and throat; and therapeutic and surgical equipment, endoscope ancillary equipment, and endotherapy devices.
Featured Article: How does a 12b-1 fee affect fund performance?
Receive News & Ratings for OLYMPUS CORP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OLYMPUS CORP/S and related companies with MarketBeat.com's FREE daily email newsletter.